Neurolief Announces Strategic Equity Investment from Sawai Group

Neurolief has announced a strategic equity investment from the Japanese pharmaceutical company, Sawai Group Holdings, which previously entered into an exclusive agreement for the development and marketing of Neurolief’s Relivion® – a pioneering non-invasive, home-wearable electroceutical therapy for migraine and depression – in Japan.

The Relivion® has recently been approved in Japan for the treatment of migraine. An application for the treatment of depression is in preparation.

We are very pleased to receive this investment from Sawai Group Holdings, which not only underscores our shared vision of using Neurolief’s groundbreaking technology to treat millions of migraine and depression patients in Japan, but also represents a shared commitment to improving the treatment of these debilitating chronic diseases,” said Scott Drees, CEO of Neurolief.

Guided by our corporate philosophy of ‘Always Putting Patients First’, we are committed to contributing to healthier lives by introducing new and innovative treatment options. With the introduction of Relivion® for home use under physician supervision, we are expanding treatment options for patients suffering from either migraine or depression,” said Mitsuo Sawai, CEO of Sawai Group Holdings.

en_GBEnglish (UK)